Phase I trial; HMR code: 24-003

Submission date	Recruitment status	[X] Prospectively registered
05/08/2024	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
12/08/2024	Deferred	Results
Last Edited	Condition category	Individual participant data
06/01/2025	Other	[X] Record updated in last year

Plain English summary of protocol

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Principal investigator

Contact name

Dr Adeep Puri

Contact details

Hammersmith Medicines Research Limited Cumberland Avenue Park Royal London United Kingdom NW10 7EW +44 20 8961 4130 rec@hmrlondon.com

Type(s)

Public, Scientific

Contact name

Dr Jeff Kent

Contact details

455 E. Eisenhower Parkway Suite 300 PMB 1048 Ann Arbor United States of America

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

1010220

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

IRAS 1010220; HMR code: 24-003; Sponsor code: SLG-TED-101

Study information

Scientific Title

Phase I trial; HMR code: 24-003 [The full scientific title will be published within 30 months after the end of the trial]

Study objectives

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 30/07/2024, London – Surrey Borders Research Ethics Committee (Equinox House, City Link, Nottingham, NG2 4LA, United Kingdom; +44 207 104 8057; surreyborders.rec@hra.nhs.uk), ref: 24/LO/0492

Study design

Pharmacokinetic and bioavailability study in up to 20 healthy volunteers

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

Healthy volunteers

Interventions

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s))

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date

08/08/2025

Eligibility

Key inclusion criteria

Healthy volunteer

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment 14/08/2024

Date of final enrolment 08/05/2025

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
Hammersmith Medicines Research Limited
Cumberland Avenue
London
United Kingdom
NW10 7EW

Sponsor information

Organisation

Sling Therapeutics, Inc.

Funder(s)

Funder type

Industry

Funder Name

Sling Therapeutics, Inc.

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet 11/11/2025 No Yes